Prot #CC-220-MM-001: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 Monotherapy and in Combination with Other Treatments in Sub

Project: Research project

Project Details

StatusActive
Effective start/end date10/10/1910/10/22

Funding

  • ICON Clinical Research, LLC (Prot #CC-220-MM-001)
  • Celgene Corporation (Prot #CC-220-MM-001)